About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 2NCT02605811

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

To investigate the response of temozolomide versus prophylactic cranial radiotherapy in preventing brain metastases in completed or partial remission limited small cell lung cancer patients.

Lead sponsor: Guangzhou Medical University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Haihong Yang, MD

CONTACT

862083062825 bjrf2009@yahoo.com

Haihng Yang, MD

CONTACT

Sponsors

Lead Sponsor

Guangzhou Medical University

We'd like to investigate the 2-year incidence rate of brain metastases in completed or partial remission limited small cell lung cancer patients who received temozolomide only for 12 months or 25-30Gy prophylactic cranial radiotherapy in preventing brain metastases.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Histological or cytological diagnosis of small-cll lung cancer histology
•2. 18 years or older
•3. Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 2
•4. Local stage SCLC without distant metastases
•5. After 1st-line chemotherapy (EP or IP) at least 4 cycles
•6. After radical radiotherapy for primary tumor and lymph node drainage area:including concurrent or sequence chemoradiotherapy
•7. CR or PR assessment by RECIST(1.0) before randomized
•8. Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5\^9/L, platelets 100 x 10\^9/L
•9. Total bilirubin 1.5 x upper limit of normal (ULN) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases
•10. Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)

Exclusion Criteria

•1. Mixed non-small cell lung cancer histology
•2. Neck and supraclavicular lymph node metastasis
•3. Be allergic to temozolomide or intolerable to radiotherapy
•4. Any unstable systemic disease
•5. Pregnant or lactating women

Related studies

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

RECRUITINGPhase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more

RECRUITINGPhase 2

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

NCT07164170 · Non-Small Cell Lung Cancer

RECRUITINGPhase 2

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NCT06364917 · Non Small Cell Lung Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 28, 2019Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment426

Start dateSep 2015

Last updatedMar 28, 2019

Condition

Small Cell Lung Cancer Metastatic Carcinoma

Locations shown

The first affiliated hospital of Guangzhou MC

Guangzhou, Guangdong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 28, 2019Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions